Yuhan Corp. will set up a solo booth at CPHI Worldwide 2026, the world’s largest pharmaceutical and biotechnology exhibition, taking place in Milan, Italy, from Oct. 6 to 8, the company said Oct. 6, as it seeks to expand its presence in global markets.
At the Milan event, Yuhan Corp. plans to showcase its strong R&D capabilities and commercialization expertise to global partners.
The company will actively promote its CDMO capabilities, supported by high-quality active pharmaceutical ingredient (API) manufacturing infrastructure secured through synergies with its subsidiary Yuhan Chemical, as well as facilities that meet global cGMP standards.
cGMP refers to current good manufacturing practices applied to pharmaceutical manufacturing facilities, processes and quality control to ensure the safety and quality of medicines. The U.S. Food and Drug Administration and other regulatory agencies use such standards to oversee and evaluate pharmaceutical manufacturing facilities.
A large number of Yuhan Corp.’s key professionals in global business, R&D and overseas sales will attend the event and hold a range of one-on-one business meetings with major pharmaceutical companies and biotechnology firms from around the world.
CPHI is the world’s largest pharmaceutical and biotechnology trade show, held each year in major European countries. It serves as a business networking platform attended by tens of thousands of industry professionals and companies involved in APIs, contract development and manufacturing, packaging and equipment worldwide.
Yuhan Corp.’s API business is continuing to see strong export performance, with contract manufacturing volumes for global multinational pharmaceutical companies steadily increasing.
In particular, global partnerships are gaining further momentum on the back of Yuhan Chemical’s proactive expansion of manufacturing capacity and rigorous quality management that meets the high standards of global regulatory agencies.
Yuhan Corp. plans to use the event to accelerate its current positive growth momentum and drive further expansion of diversified global CDMO orders.
A Yuhan Corp. official said, “Participating in CPHI is an important opportunity to demonstrate Yuhan Corp.’s global commercialization capabilities and technological expertise in major markets worldwide. Based on our innovative pipeline and globally competitive CDMO capabilities, we will strengthen cooperation with existing partners and accelerate our progress toward becoming one of the world’s top 50 pharmaceutical companies.”